Dr. Reddy’s Delays Semaglutide Supplies Over API Quality Issue

Dr. Reddy’s Laboratories announced on July 9, 2026, that it is delaying commercial distribution of its semaglutide products—a key metabolic therapy used for diabetes and obesity management—following the discovery that certain batches were "out of specification." The company, a prominent player in the generic GLP-1 (glucagon-like peptide-1) space, attributed the supply disruption to an issue involving the Active Pharmaceutical Ingredient (API).

During an investor conference call, company executives clarified that the impurity was linked to the chemical reaction process of the API and was subsequently detected during formulation testing. The firm emphasized that the issue is strictly a manufacturing process deviation and does not require any changes to existing production equipment.

Supply Impact and Resolution Timeline

Addressing concerns regarding the availability of the drug, particularly in the Canadian market where the company recently launched its generic semaglutide injection, executives stated that existing stock already in the market remains unaffected and is safe for use. However, the company acknowledged a projected supply halt that will persist through September.

"The actual supply to the market can resume in late October to early November, provided the issue is resolved," officials stated during the conference. The company remains on track to supply between 6 and 7 million semaglutide pens between the third and fourth quarters, despite the current pause. Furthermore, Dr. Reddy’s clarified that there is no question of a product recall, as the affected batches did not reach commercial distribution. The firm also noted it may need to write down the value of some inventory due to the deviation.

Regulatory and Safety Stance

Dr. Reddy’s Laboratories was quick to distinguish this manufacturing hurdle from systemic safety concerns. The company confirmed that there is no impact on patient safety, and all existing global regulatory filings remain valid.

The firm also clarified that a separate, unrelated batch recall previously reported in India had no connection to the current API-related issue. Dr. Reddy’s management is currently investigating the root cause of the reaction process fault and implementing corrective measures to resume consistent production.

Why It Matters

For the pharmaceutical industry and investors, the supply disruption highlights the complexities of manufacturing high-demand, high-complexity generic biologics like semaglutide. As patent expiries open the market to generic competition, the ability to maintain consistent quality in API synthesis is critical. For patients, the stability of supply is paramount, as demand for GLP-1 therapies continues to outpace global manufacturing capacity.

Key Facts at a Glance

• Issue: Out-of-specification batches due to an impurity linked to the API reaction process.

• Supply Status: Commercial supplies are halted until at least late October or early November 2026.

• Safety: The company confirms no impact on patient safety; no product recall has been initiated.

• Market Impact: Supplies currently in the Canadian market are unaffected and safe for use.

• Projection: The company remains committed to supplying 6–7 million pens between Q3 and Q4.

FAQ Section

1. Is there a recall of semaglutide products?

No. Dr. Reddy’s has confirmed that there is no recall because the batches found to be out of specification did not reach the commercial market.

2. Are the semaglutide products currently in pharmacies safe?

Yes. Executives stated that whatever product has already been sent to the market, including in Canada, is unaffected and safe for use.

3. What caused the supply delay?

The delay was caused by an impurity detected during the formulation stage, which the company traced back to the API reaction process.

Source: Dr. Reddy’s Laboratories Investor Relations, BSE Limited, National Stock Exchange of India (NSE).